In an effort to determine relapse rates in breast-feeding and non-breast-feeding mothers with multiple sclerosis (MS) Few studies have been conducted regarding the effects of breast-feeding on relapse rates during the postpartum period among women with multiple sclerosis (MS), and those that have been conducted report dissimilar findings. Retrospective studies report relapse rates between .375 and .440 for breast-
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In an effort to determine relapse rates in breast-feeding and non-breast-feeding mothers with multiple sclerosis (MS) as well as differences in symptom prevalence between relapsing and non-relapsing mothers, weekly diaries through the first six postpartum months were kept by mothers to record the frequency and percentages of infant feeding by breast or formula and health problems that the mothers experienced. Of 140 mothers who breast-fed their infants, 35 (25%) experienced at least one neurologist-confirmed MS relapse during the first six months and 47 (33.6%) during the 12-month period; for nonbreast-feeding mothers, 18 (51.4%) experienced relapse by six months and 22 (61.1%) by 12 months. MS relapse during pregnancy predicted increased relapse during the first three postpartum months while an increased percentage of infant feedings by breast predicted decreased relapse. Relapse the year before pregnancy and during pregnancy predicted increased relapse during the four-to six-month postpartum period. Length of time on immunomodulating therapy since delivery predicted increased relapse at seven to nine months. MS relapse during pregnancy predicted increased relapse at the 10-to 12-month period. For non-breast-feeding mothers none of the predictors of relapse were significant for the three-month period except use of immunomodulating therapy during the four-to sixmonth period when such use was associated with increased relapse. Relapsing compared with non-relapsing mothers reported significantly more MS-related symptoms during the three-month postpartum period. Decreased relapse rates during the first three months following delivery among breast-feeding mothers compared with non-breast-feeding mothers have implications for encouraging women with MS who wish to breast-feed their infants to do so, particularly if their pregnancy was free of relapse. Women with MS are also encouraged to postpone the initiation of immunomodulating therapy until three months following delivery or when breast-feeding is discontinued.
feeding and .305 and 1.00 for non-breast-feeding mothers during the first nine and 12 months postpartum. 1, 2 In a prospective study consisting of four breast-feeding and four non-breast-feeding mothers, Birk et al 3 reported annualized relapse rates of 3.0 and 1.74 for the three-and six-month postpartum periods, respectively. Another prospective study reported relapse rates of 1.2 at three months and .9 at six months postpartum for breast-feeding mothers compared with 1.30 and 1.0 respectively for non-breast-feeding mothers. 4 These studies varied in sample size and, with the exception of one study, 4 failed to control for potential confounding factors that may influence relapse rates.
Unless potentially confounding influences on relapse rates are controlled, the true effects of breastfeeding on relapse rates cannot be discerned. The purpose of the current prospective study was to investigate further the effects of breast-feeding on relapse rates of mothers with MS who breast-fed their infants compared to those who did not, controlling for confounding factors before, during, and following the birth of their infants. Additionally, MS-related symptoms were examined between relapsing and non-relapsing mothers during the 12-month postpartum period.
METHODS
Study Design and Recruitment of Subjects
We used a prospective design to compare breast-feeding and non-breast-feeding mothers with MS on relapse rates and symptoms at one, three, six, nine, and 12 months postpartum. Mothers were recruited from the United States and Canada by Web site announcements through the Consortium of Multiple Sclerosis Centers/North American Research Committee (CMSC/NARCOMS), in newsletters of local chapters of the National Multiple Sclerosis Society (NMSS), and at MS outpatient clinics. The study was approved by Institutional Review Boards for Protection of Human Subjects among the recruitment agencies and the principal investigator's university. Included were women diagnosed with MS who had not yet delivered or whose infant was 1 month old or younger.
Procedure
Women interested in participating in the study contacted the investigators by telephone or e-mail; other potential subjects were referred by staff members from MS outpatient clinics. Pregnant women (two thirds of the sample) were mailed consent forms that described elements of informed consent and were instructed to notify the principal investigator when delivery occurred, at which time the one-month study materials were sent. The signed consent form gave permission for the principal investigator to contact the subject's designated neurologist for confirmation of an MS relapse, should one occur. MS relapse was defined as the appearance or worsening of symptoms of neurologic dysfunction lasting more than 24 hours. Women who already had delivered (one third of the sample) were sent the consent form and the one-month study materials consisting of a Personal Data Inventory, MS-Related Symptom Scale, and three Health Diaries for the first three months postpartum. Self-addressed stamped envelopes were included for returning the completed material to the principal investigator. These study materials were sent to participants again at three, six, nine, and 12 months postpartum.
Sample
Of 191 mothers who sought information about the study, 176 were enrolled. Of the 176 mothers, one was removed because she was subsequently diagnosed with Devic's disease. Of the 175 mothers, 140 (80%) breast-fed their infants for part or all of the 12-month period with an average of 5.92 ± 4.10 months and 35 (20%) did not breast-feed. Of the non-breast-feeding mothers, 34 elected not to breastfeed and one mother, after an unsuccessful attempt for the first two days postpartum, decided to use total formula feedings. Breast-feeding mothers, on average, were about two years older, had one year more education, and experienced six months more duration of MS than did non-breast-feeding mothers (see Table 1 ). Of the breast-feeding mothers, 134 (95.7%) were married, compared with 31 (88.6%) non-breast-feeding mothers. The current birth represented the firstborn for 61 (43.6%) breast-feeding and 19 (54.3%) non-breast-feeding mothers. Most mothers in both groups were white (see Table 1 ) and had been classified with relapsing-remitting MS (see Table 2 ). 
The Personal Data Inventory sought information about the mother's age, educational level, age at MS diagnosis, marital status, number of children, ethnicity, and health status during pregnancy and delivery.
MS-Related Symptom Scale (MS-RS)
The 26-item MS-RS consists of five factored subscales: motor, brainstem, sensory, mental/emotional, and elimination. 5 Respondents rated how frequently they experienced each symptom on a scale ranging from 0 (never) to 5 (always). Ratings were dichotomized as 1 (never or almost never) and 2 (occasionally to always). Satisfactory reliability and validity have been reported for the MS-RS. [5] [6] [7] Interrater agreement between the MS-RS subscales and Kurtzke Functional Systems ranged between 73% and 86%.6 Reliability coefficients ranged between .51 and .91 for the subscales in the current study.
Mother's Diary
Monthly diaries were used for the first six postpartum months to record weekly averages for percentage of feedings given each day by breast and/or formula. Prolactin levels are dependent upon the interval between sucking episodes and intensity. 8, 9 Infant feeding by breast was coded as 0 (none), 1 (1% to 49%), 2 (50% to 79%), and 3 (80% to 100%) for each of the first six months. Codes assigned for breastfeeding at nine and 12 months were 0 (none) and 1 (some). Table 3 describes the percentage of infant feedings given by breast during the 12 postpartum months. The health diaries were also used to describe any health problems experienced by the mother that required telephone calls or office visits for medical care. At nine and 12 months, mothers were asked to indicate if immunomodulating drugs were being taken and, if so, which ones and when they were started. To evaluate the ongoing and cumulative effect of immunomodulating therapy, values for its use were calculated from the date following birth when therapy was initiated to the specific assessment month. For example, a mother who started therapy at 1.5 months following birth received a value of 1.5 at three months, 4.5 at six months, 7.5 at nine months, and 10.5 at 12 months. Mothers were also queried about health problems they may have experienced, and mothers who breast-fed their infants through six months were queried as to when they discontinued breast-feeding or if they were currently breast-feeding.
Information from mothers regarding relapse the year before pregnancy and their MS classification was sought at or shortly following the 12-month health assessment. Mothers who were uncertain about relapse the year before pregnancy or their MS classification gave permission for the first author to contact their neurologist.
Analysis of Data
Descriptive statistics were used to describe study variables and inferential statistics to compare breastfeeding and non-breast-feeding groups on annualized relapse rates and MS symptoms. Due to missing data regarding MS relapse the year before pregnancy for six (4.3%) breast-feeding and three (8.6%) non-breast-feeding mothers, imputed values10 were derived for missing data by regressing number of MS relapses the year before pregnancy on number of MS relapses during pregnancy, MS duration, and the age of the mother. Imputed values from nine of the mothers together with the available data were used in binary logistic regression to predict variables related to relapse rates during three-month postpartum period. Statistically significant results are reported at P < .05 and are presented in Tables 1  through 6 . Table 3 Percentage of infant feedings given by breast-feeding during the first six postpartum months and percentage of mothers continuing to breast-feed at nine and 12 months postpartum None 1% to 49% 50% to 79% 80% to 100% *These mothers breast-fed their infants for less than one month.
RESULTS
Percentage of Women Experiencing Relapse and Percentage Receiving Immunomodulating Therapy
Of 140 mothers who breast-fed their infants part or all of the first six postpartum months, 35 (25%) experienced one or more MS relapses compared with 18 (51.4%) of 35 non-breast-feeding mothers.
During the 12-month postpartum period, 47 (33.6%) breast-feeding mothers experienced one or more MS relapses compared with 22 (62.9%) non-breast-feeding mothers. Average time to first relapse was significantly earlier among non-breast-feeding (3.12 months) compared with breast-feeding mothers (4.99 months). Of mothers who experienced relapse and began therapy during the 12-month postpartum period, 21.4% began therapy within two months of the relapse. About two thirds of non-breast-feeding mothers began taking one of the immunomodulating drugs by three months postpartum; this proportion increased to 80% by 12 months postpartum. In contrast, 16.4% of breast-feeding mothers were receiving immunomodulating drugs at three months, which increased to 53.6% by 12 months postpartum (see Table 4 ). For some mothers, anecdotal diary comments suggested that the presence of relapse influenced their decision to start immunomodulating therapy. Group differences: *X2 = 9.263, P = .002; †X2 = 9.112, P = .003; ‡t = 2.200, P = .031
Seven (5%) mothers from the breast-feeding group received immunomodulating therapy concurrent with breast-feeding for an average of 6.6 months with a range between 3.7 and 11.1 months. Four of these mothers experienced a relapse shortly before starting therapy, two experienced a relapse after initiation of therapy and one mother experienced no relapse during the 12 postpartum months. Of the seven mothers, five received interferon (IFN) beta-1a therapy, one received glatiramer acetate, and one received IFN beta-1b therapy.
Relapse Rates Without Control for Confounding Variables
Relapse rates for the two groups taking into account the number of relapses per mother, without control for potential confounding variables, were found to be significantly lower for the breast-feeding compared to non-breast-feeding mothers during the zero to three and seven to nine month postpartum periods (see Table 5 ). Although not statistically significant, lower relapse rates were also shown for breast-feeding compared to non-breast-feeding mothers during four to six and 10 to 12 postpartum months. Relapse rates during the pregnancy period were higher for non-breast-feeding compared to breast-feeding mothers and approached being statistically significant. Relapse rates during the year preceding the pregnancy period were similar for both groups of mothers (see Table 5 ). Table 5 Relapse rate of mothers with MS in relation to whether or not they breast-fed their infants
Relapse Rates Controlling for Confounding Variables
Binary logistic regression was used to determine predictors of none versus one or more relapses for zero to three, four to six, seven to nine, and 10-12 month postpartum periods separately for breast-feeding and non-breast-feeding groups. There was controlling for potentially confounding variables pertaining to number of relapses the year before pregnancy, number of relapses during pregnancy, age of mother at delivery, duration of MS since diagnosis, educational level, and use of immunomodulating therapy. The variables relative to mother's age at delivery, MS duration, and educational level failed to emerge as significant predictors of relapse at any of the postpartum periods. Breast-feeding mothers who experienced MS relapse during pregnancy were six times more likely to experience MS relapse during the first three months postpartum than were mothers who did not experience a relapse during pregnancy. However, after controlling for the effects of MS relapse during pregnancy, the mothers who gave the majority of infant feedings by breast during the first three months postpartum experienced 63% fewer MS relapses than those mothers who stopped or markedly reduced the percent of infant feedings by breast (see Table 6 for statistical results). Table 6 Logistic regression used to predict MS relapse during the postpartum
During the four to six month postpartum period, mothers in the breast-feeding group who experienced relapse the year before and during pregnancy were two and three times, respectively, more likely to experience relapse during the four to six months postpartum than those who did not experience such relapses. Breast-feeding did not emerge as having a significant effect on MS relapse rate during the four to six months postpartum after controlling for the confounding variables (see Table 6 for statistical results).
During the seven to nine month postpartum period, mothers in the breast-feeding group who began immunomodulating therapy were one and one third times more likely to experience relapse during this period than those who did not receive immunomodulating therapy. Breast-feeding did not emerge as having a significant effect on MS relapse rate during the seven to nine months postpartum after controlling for the confounding variables (see Table 6 for statistical results).
During the 10 to 12 month postpartum period, mothers in the breast-feeding group who experienced MS relapse during pregnancy were twice as likely to experience relapse during the 10 to 12 month period than those who did not experience relapse during pregnancy. Again, breast-feeding did not emerge as having a significant effect on MS relapse rate during 10 to 12 months postpartum after controlling for the confounding variables (see Table 6 for statistical results).
For non-breast-feeding mothers, only the confounding variables were examined at zero to three, four to six, seven to nine, and 10 to12 month postpartum periods. None of the confounding variables including number of relapses the year before pregnancy, number of relapses during pregnancy, age of mother at delivery, duration of MS since diagnosis, educational level, and use of immunomodulating therapy were significant predictors of MS relapse during the zero to three, seven to nine, and 10 to 12 month postpartum periods. However, use of immunomodulating therapy was a significant predictor of relapse during the four to six month period. Mothers who used immunomodulating therapy were 1.66 times more likely to have experienced relapse during this period than mothers who did not experience relapse (see Table 6 for statistical results).
Symptoms During MS Relapses
Not unexpectedly, mothers who experienced MS relapse reported more symptoms than mothers who did not experience a relapse. Significantly more motor symptoms were reported by relapsing mothers at one, nine, and 12 months postpartum; more brainstem at six months; more sensory at one, six, nine, and 12 months; more mental/emotional at one, three, six, and nine months; and more elimination symptoms at one, three, six, nine, and 12 months (see Figure 1) . The prevalent symptom among the groups was sensory symptoms followed by mental/emotional, motor, brainstem, and elimination.
DISCUSSION
MS relapse rates found in the current study for non-breast-feeding compared with breast-feeding mothers were more than triple for the one to three postpartum months, about double for the four to six postpartum months, and nearly triple for the seven to nine postpartum months. However, little difference was observed between these two groups during the 10 to 12 postpartum months, which reflected rates relatively similar to those of the year before pregnancy. Relapse rates during pregnancy, although low and not statistically significant, were higher among non-breast-feeding than breastfeeding mothers.
Relapse rates the year before and during pregnancy found in the current study for breast-feeding and non-breast-feeding mothers were relatively similar to those reported by Confavreux et al. 4 In contrast, relapse rates were less than one half the rate reported by Confavreux et al 4 during the first three postpartum months, about half at four to six months, less than half at seven to nine months, and slightly less at 10 to 12 months. Of particular import is the finding in the current study that breast-feeding compared to non-breast-feeding mothers had statistically significantly fewer relapses during the zeroto three-month period after controlling for the effects of relapse the year before and during pregnancy, age of mother, duration of MS, educational level and use of immunomodulating therapy. These findings are in contrast to Confavreux et al 4 who did not find significant differences between relapse among breast-feeding and non-breast-feeding groups for any of the three-month postpartum periods despite adjustment for the mother's age, duration of MS, and occurrence of relapse one year before and during pregnancy. However, Confavreux et al 4 did find significantly fewer relapses among breast-feeding mothers when relapses during the year before pregnancy, pregnancy period, and year following pregnancy were combined.
Breast-feeding mothers reported one third the relapse rate of non-breast-feeding mothers at three months postpartum, a rate comparable to the yearly rate reported by persons with MS who receive one of the immunomodulating therapies: IFN beta-1b, glatiramer acetate, and IFN beta-1a. 11 During the first six and 12 postpartum months the relapse rate for breast-feeding mothers was less than one fifth and one half, respectively, that of non-breast-feeding mothers.
It is unclear why some mothers who were receiving immunomodulating therapy during the postpartum period experienced more relapses than mothers who were not receiving such therapy. One reason might be incomplete protection as a result of medication titration, a procedure frequently used when initiating therapy aimed at minimizing drug adverse effects. 12 Another reason might be the immunosuppressant drug used being less effective than another one, or possibly a need for combining therapies. 13 Although not statistically significant, proportionately more non-breast-feeding mothers (n = 7, 20%) compared to breast-feeding mothers (n = 12, 8.6%) reported experiencing MS relapse during their pregnancy. Experiencing a relapse during pregnancy may be a deterrent to breast-feeding and a possible reason for initiating or resuming immunomodulating therapy soon after giving birth. However, of the seven non-breast-feeding mothers who experienced relapse during their pregnancy, only four were receiving immunomodulating therapy by three months postpartum. This suggests that factors other than immunomodulating therapy influence the mother's decision to forego breast-feeding.
One explanation for fewer relapses experienced by breast-feeding compared to non-breast-feeding mothers may be increased circulating levels of prolactin, which has immunomodulating capabilities. 14 Prolactin levels in fully breast-feeding mothers are triple those of non-breast-feeding mothers during the first 12 to 20 postpartum weeks and then gradually decline. 8 The decline in prolactin level is hastened when infant sucking at the breast is diminished by supplementation with artificial milk and/or other foods. 8, 9 In central Africa, where breast-feeding is sustained for two years and mothers give the breast more than six times per day, serum prolactin levels did not decline significantly during the first postpartum year. 15 The immunosuppressant effect of increased levels of prolactin may be due in part to a decreased natural killer cell activity in the presence of hyperprolactinemia. 14, 16 Another explanation for the fewer relapses experienced by breast-feeding compared to non-breastfeeding mothers may be the immune suppression resulting from an increased level of serum cortisol that accompanies breast-feeding due to the infant sucking that stimulates release of ACTH and subsequent increase in cortisol production. 17 Corticosterones inhibit antigen-induced T cell proliferation by macrophages. 18 Retrospective 1, 19, 20 and prospective studies 3, 4, [21] [22] indicate that fewer relapses occur during the pregnancy period, but they increase two to three times during the three to six month postpartum period compared to nonpregnant and nonpostpartum periods. Both prolactin 23 and cortisol 24 levels increase significantly during the pregnancy period and may contribute to the apparent immune suppression that is evidenced in pregnant women with MS.
Research is needed to investigate the role that elevated prolactin and cortisol levels may have on MS relapse rates of mothers who breast-feed their infants. These hormones may have immune modulating action in which decreases in CD4+ killer and increases in CD8+ suppressor T cells or related cytokines occur.
The prevalence of motor, brainstem, and mental/emotional symptoms found in the current study for nonrelapsing mothers is similar to that commonly experienced during relapsing-remitting MS 25 but is much higher for the relapsing mothers. However, the prevalence of sensory and elimination symptoms among nonrelapsing mothers in the current study was higher by approximately double and triple, respectively, than reported by Whitney. 25 The increased prevalence of elimination symptoms may have been associated with weakened pelvic floor muscles due to childbirth, making this area vulnerable to incontinence during MS relapse.
Perhaps the most serious challenge to these data concerns the possibility that some mothers may not have had definite MS. However, MS relapses reported by the mothers were confirmed by their attending neurologists. Further, the mothers' reports of symptoms are consistent with MS and MS relapse.
CONCLUSION
Decreased relapse rates during the first three months following birth among breast-feeding mothers, after controlling for mother's age, MS duration, educational level, use of immunomodulating drugs, and relapses the year before and during pregnancy, compared to non-breast-feeding mothers has implications for encouraging women with MS who wish to breast-feed their infants to do so, particularly if their pregnancy was free of relapse, and to postpone the initiation of immunomodulating therapy until after three months or when breast-feeding is discontinued. Although the study findings cannot conclude that breast-feeding causes decreased relapse rates during the postpartum period, the significant association between increased breast-feeding and decreased postpartum MS relapse warrants further study. Studies are needed to determine prolactin and cortisol levels in breast-feeding mothers together with levels of CD4+ and CD8+ T cells and related cytokines to determine if they are associated with postpartum relapse.
